Literature DB >> 13150518

A clinical appraisal of pentapyrrolidinium (M&B 2050) in hypertensive patients.

E D FREIS, E A PARTENOPE, L S LILIENFIELD, J C ROSE.   

Abstract

Entities:  

Keywords:  AUTONOMIC DRUGS/therapeutic use; HYPERTENSION/therapy; MUSCLE RELAXANTS/therapeutic use; PYRROLES/therapeutic use

Mesh：

Substances：

Year:  1954        PMID： 13150518     DOI： 10.1161/01.cir.9.4.540

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  7 in total

1.  The actions of heterocyclic bisquaternary compounds, especially of a pyrrolidinium series.

Authors:  D F MASON; R WIEN
Journal:  Br J Pharmacol Chemother       Date:  1955-03

2.  Significant clinical variations in hypertension.

Authors:  M J MOSELY
Journal:  J Natl Med Assoc       Date:  1955-07       Impact factor: 1.798

3.  Ansolysen in the treatment of arterial hypertension.

Authors:  A DAVIGNON; G LEMIEUX; J GENEST
Journal:  Can Med Assoc J       Date:  1956-05-15       Impact factor: 8.262

4.  Experience in the treatment of hypertension with pentapyrrolidinium (ansolysen) in a hypertension outpatient clinic.

Authors:  H Z POMERANTZ; S BARSKY; L GORDON; J WENER
Journal:  Can Med Assoc J       Date:  1957-08-15       Impact factor: 8.262

5.  [Clinical studies on the deblocking properties of prostigmine in ganglion blockade induced by ecolid and pendiomide].

Authors:  J GOERRE
Journal:  Klin Wochenschr       Date:  1957-11-15

6.  The hypotensive action of mercamylamine.

Authors:  A E DOYLE; E A MURPHY; G H NEILSON
Journal:  Br Med J       Date:  1956-11-24

7.  [New drugs for the management of hypertension].

Authors:  R W GIFFORD
Journal:  Klin Wochenschr       Date:  1956-01-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.